<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), has announced results from the Phase 2b QUASAR Induction study of Tremfya (guselkumab) in active ulcerative colitis. The findings were presented at the Congress of the European Crohn’s and Colitis Organization (ECCO).
...read full article on Benzinga
